Acta Diabetologica

, 46:279

Sulphonylureas and cancer: a case–control study

Authors

  • Matteo Monami
    • Department of Critical Care Medicine and Surgery, Unit of Gerontology and GeriatricsUniversity of Florence and Azienda Ospedaliero-Universitaria Careggi
  • Caterina Lamanna
    • Department of Critical Care Medicine and Surgery, Unit of Gerontology and GeriatricsUniversity of Florence and Azienda Ospedaliero-Universitaria Careggi
  • Daniela Balzi
    • Epidemiology Unit
  • Niccolò Marchionni
    • Department of Critical Care Medicine and Surgery, Unit of Gerontology and GeriatricsUniversity of Florence and Azienda Ospedaliero-Universitaria Careggi
    • Department of Critical Care Medicine and Surgery, Unit of Gerontology and GeriatricsUniversity of Florence and Azienda Ospedaliero-Universitaria Careggi
Original Article

DOI: 10.1007/s00592-008-0083-2

Cite this article as:
Monami, M., Lamanna, C., Balzi, D. et al. Acta Diabetol (2009) 46: 279. doi:10.1007/s00592-008-0083-2

Abstract

This study was aimed at the assessment of incidence of malignancies in type 2 diabetic patients treated with different sulphonylureas. A matched case–control study was performed. Cases were 195 diabetic patients aged 69.0 ± 9.2 years who had an incident malignancy. Controls were 195 diabetic patients, unaffected by cancer, who were matched with the corresponding case for age, sex, duration of diabetes, BMI, HbA1c, comorbidity, smoking and alcohol abuse. Exposure to hypoglycaemic drugs during the 10 years preceding the event (or matching index date) was assessed. After adjusting for concomitant therapies, exposure to metformin and gliclazide for more than 36 months was associated with a significant reduction in the risk of cancer (adj. ORs with 95% CI: 0.28 (0.13–0.57), p < 0.001, and 0.40 (0.21–0.57), p = 0.004, respectively). Conversely, use of glibenclamide for at least 36 months was associated with increased incidence of malignancies (adj. OR 2.62 (1.26–5.42); p = 0.009). Treatment with insulin, thiazolidinediones, or acarbose, was not associated with significant differences in the incidence of cancer. Long-term treatments with individual sulphonylureas could have differential effects on the risk of cancer. In particular, the possible protective effect of gliclazide, as well as the risk associated with glibenclamide, deserves further investigation.

Keywords

CancerDiabetes mellitusCase–control studyHypoglycaemic DrugsSulphonylureas

Copyright information

© Springer-Verlag 2008